BR112015015468B8 - Composto, e, composição farmacêutica - Google Patents
Composto, e, composição farmacêuticaInfo
- Publication number
- BR112015015468B8 BR112015015468B8 BR112015015468A BR112015015468A BR112015015468B8 BR 112015015468 B8 BR112015015468 B8 BR 112015015468B8 BR 112015015468 A BR112015015468 A BR 112015015468A BR 112015015468 A BR112015015468 A BR 112015015468A BR 112015015468 B8 BR112015015468 B8 BR 112015015468B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- compounds
- pharmaceutical composition
- receptor antagonists
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
COMPOSTO, E, COMPOSIÇÃO FARMACÊUTICA. São descritos compostos da Fórmula G1 (estruturalmente representados): onde "RG3", "Rd1" a "Rd4", "n", "m", "p", "W", "X", "Y" e "Z" são aqui definidos, compostos estes que são antagonistas do receptor de A2A. Também são aqui descritos os usos dos compostos aqui descritos como antagonistas do receptor de A2a no tratamento ou prevenção potenciais de distúrbios e doenças neurológicas em que os receptores de A2A estão envolvidos. Também são aqui descritas composições farmacêuticas compreendendo estes compostos e usos destas composições farmacêuticas.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2012/087865 | 2012-12-28 | ||
PCT/CN2012/087865 WO2014101120A1 (en) | 2012-12-28 | 2012-12-28 | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
PCT/CN2013/076853 WO2014101373A1 (en) | 2012-12-28 | 2013-06-06 | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder |
CNPCT/CN2013/076853 | 2013-06-06 | ||
PCT/US2013/076781 WO2014105666A1 (en) | 2012-12-28 | 2013-12-20 | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015015468A2 BR112015015468A2 (pt) | 2017-07-11 |
BR112015015468B1 BR112015015468B1 (pt) | 2021-10-26 |
BR112015015468B8 true BR112015015468B8 (pt) | 2023-04-25 |
Family
ID=51019745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015015468A BR112015015468B8 (pt) | 2012-12-28 | 2013-12-20 | Composto, e, composição farmacêutica |
Country Status (22)
Country | Link |
---|---|
US (2) | US9708347B2 (pt) |
EP (1) | EP2945632B1 (pt) |
JP (1) | JP6306049B2 (pt) |
KR (1) | KR102165113B1 (pt) |
AU (1) | AU2013370977B2 (pt) |
BR (1) | BR112015015468B8 (pt) |
CA (1) | CA2896056C (pt) |
CY (1) | CY1120258T1 (pt) |
DK (1) | DK2945632T3 (pt) |
ES (1) | ES2667477T3 (pt) |
HR (1) | HRP20180678T1 (pt) |
HU (1) | HUE037950T2 (pt) |
LT (1) | LT2945632T (pt) |
ME (1) | ME03034B (pt) |
MX (1) | MX370017B (pt) |
NO (1) | NO2945632T3 (pt) |
PL (1) | PL2945632T3 (pt) |
PT (1) | PT2945632T (pt) |
RS (1) | RS57162B1 (pt) |
RU (2) | RU2018136104A (pt) |
SI (1) | SI2945632T1 (pt) |
WO (3) | WO2014101120A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3253390B1 (en) * | 2015-02-06 | 2022-04-13 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
EP3307067B1 (en) * | 2015-06-11 | 2022-11-02 | Merck Sharp & Dohme LLC | Aminopyrazine compounds with a2a antagonist properties |
WO2017008205A1 (en) * | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
WO2017034994A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity |
US10568882B2 (en) | 2015-08-21 | 2020-02-25 | Srx Cardio, Llc | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use |
WO2017034990A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity |
EP3394061B1 (en) | 2015-12-23 | 2020-03-11 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2017107087A1 (en) * | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
CN108884061B (zh) | 2017-01-13 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 |
CN110382499B (zh) | 2017-02-27 | 2023-01-03 | 贝达药业股份有限公司 | Fgfr抑制剂及其应用 |
WO2018166493A1 (zh) | 2017-03-16 | 2018-09-20 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
RU2748993C1 (ru) * | 2017-09-28 | 2021-06-02 | СиСТОУН ФАРМАСЬЮТИКАЛС (СУЧЖОУ) КО., ЛТД. | Производное с конденсированным кольцом в качестве ингибитора рецептора a2a |
EP3723754A4 (en) | 2017-12-13 | 2021-05-19 | Merck Sharp & Dohme Corp. | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES |
JP2021512959A (ja) | 2018-02-06 | 2021-05-20 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. | ピラゾロ[1,5−a][1,3,5]トリアジン−2−アミン誘導体、その製造法、およびその医薬用途 |
MA54298A (fr) | 2018-11-30 | 2022-03-09 | Merck Sharp & Dohme | Dérivés amino triazolo quinazoline 9-substitués utiles en tant qu'antagonistes du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
EP3785734B1 (en) | 2019-03-26 | 2023-04-12 | Novel Pharma Inc. | Long-acting fatty acid-binding gnrh derivative and pharmaceutical composition comprising same |
TW202142538A (zh) | 2020-02-07 | 2021-11-16 | 美商迦舒布魯姆生物有限公司 | 雜環glp-1促效劑 |
CN112159411A (zh) * | 2020-10-15 | 2021-01-01 | 南京工业大学 | 一种三氟甲基取代嘧啶并[1,3]二氮杂*化合物及其制备方法 |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713383A (en) * | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
EP0181282A1 (de) * | 1984-10-01 | 1986-05-14 | Ciba-Geigy Ag | Triazolochinazolinverbindungen |
IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
DE69428977T2 (de) * | 1993-07-27 | 2002-07-11 | Kyowa Hakko Kogyo Kk | Arzneimittel gegen Parkinsonsche Krankheit |
US5736564A (en) | 1994-06-20 | 1998-04-07 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
US5571775A (en) * | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
US5929106A (en) | 1997-10-27 | 1999-07-27 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
ATE293627T1 (de) | 2000-05-26 | 2005-05-15 | Schering Corp | Adenosin a2a rezeptor antagonisten |
AU2001274287A1 (en) * | 2000-06-20 | 2002-01-02 | Nour Eddin Ajan Alhadid | Electrical drive line |
US6358964B1 (en) * | 2000-07-26 | 2002-03-19 | King Pharmaceuticals Research And Development, Inc. | Adenosine, A3 receptor modulators |
GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
BR0312913A (pt) | 2002-07-25 | 2005-07-12 | Pharmacia Italia Spa | Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo |
BR0317436A (pt) * | 2002-12-19 | 2005-11-16 | Schering Corp | Usos de antagonistas do receptor a2a de adenosina |
WO2004092173A2 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
PL1622912T3 (pl) * | 2003-04-23 | 2009-11-30 | Schering Corp | 2-ALKINYLO i 2-ALKENYLO-PIRAZOLO-[4,3-E]-1,2,4-TRIAZOLO-[1,5-C]-PIRYMIDYNY JAKO ANTAGONIŚCI RECEPTORA ADENOZYNOWEGO A2A |
AR056080A1 (es) | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
CN101506215A (zh) | 2006-06-26 | 2009-08-12 | 先灵公司 | 腺苷A2a受体拮抗剂 |
WO2009032754A2 (en) * | 2007-08-31 | 2009-03-12 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
US8435994B2 (en) * | 2009-11-16 | 2013-05-07 | Merck Sharp & Dohme Corp. | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists |
WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
WO2014101113A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
-
2012
- 2012-12-28 WO PCT/CN2012/087865 patent/WO2014101120A1/en active Application Filing
-
2013
- 2013-06-06 WO PCT/CN2013/076853 patent/WO2014101373A1/en active Application Filing
- 2013-12-20 BR BR112015015468A patent/BR112015015468B8/pt active IP Right Grant
- 2013-12-20 HU HUE13866588A patent/HUE037950T2/hu unknown
- 2013-12-20 RS RS20180410A patent/RS57162B1/sr unknown
- 2013-12-20 RU RU2018136104A patent/RU2018136104A/ru unknown
- 2013-12-20 MX MX2015008481A patent/MX370017B/es active IP Right Grant
- 2013-12-20 PL PL13866588T patent/PL2945632T3/pl unknown
- 2013-12-20 WO PCT/US2013/076781 patent/WO2014105666A1/en active Application Filing
- 2013-12-20 NO NO13866588A patent/NO2945632T3/no unknown
- 2013-12-20 US US14/655,648 patent/US9708347B2/en active Active
- 2013-12-20 DK DK13866588.0T patent/DK2945632T3/en active
- 2013-12-20 AU AU2013370977A patent/AU2013370977B2/en active Active
- 2013-12-20 EP EP13866588.0A patent/EP2945632B1/en active Active
- 2013-12-20 KR KR1020157020147A patent/KR102165113B1/ko active IP Right Grant
- 2013-12-20 PT PT138665880T patent/PT2945632T/pt unknown
- 2013-12-20 ES ES13866588.0T patent/ES2667477T3/es active Active
- 2013-12-20 JP JP2015550682A patent/JP6306049B2/ja active Active
- 2013-12-20 RU RU2015131148A patent/RU2671628C2/ru active
- 2013-12-20 SI SI201330980T patent/SI2945632T1/en unknown
- 2013-12-20 LT LTEP13866588.0T patent/LT2945632T/lt unknown
- 2013-12-20 ME MEP-2018-97A patent/ME03034B/me unknown
- 2013-12-20 CA CA2896056A patent/CA2896056C/en active Active
-
2017
- 2017-02-02 US US15/423,238 patent/US10011615B2/en active Active
-
2018
- 2018-04-27 HR HRP20180678TT patent/HRP20180678T1/hr unknown
- 2018-05-04 CY CY20181100472T patent/CY1120258T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015015468B8 (pt) | Composto, e, composição farmacêutica | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
BRPI0910388A2 (pt) | agentes terapêutico antivirais. | |
BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
BR112015012555A2 (pt) | derivados de benzimidazol como antagonistas de ep4 | |
BR112015022566A2 (pt) | composto e composição farmacêutica | |
BR112015030595A2 (pt) | moduladores de receptor de estrogênio de azetidina e usos dos mesmos | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
BR112013003864A2 (pt) | compostos de pirrolpirimidina e usos dos mesmos | |
BR112014007163A2 (pt) | composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida | |
WO2013153479A3 (en) | Indole and indazole compounds that activate ampk | |
BR112012020558A2 (pt) | moduladores do receptor de androgênio e seus usos | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
BR112012024712A2 (pt) | antagonistas do receptor vaniloide trpv1 com uma porção bicíclica | |
UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
BR112014012056A8 (pt) | compostos farmacêuticos | |
PH12014502241A1 (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
DOP2014000059A (es) | Derivados de estra1,3,5(10),16tetraen3carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
UY33278A (es) | Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |